Review of NICE Technology Appraisal Guidance No 55; paclitaxel for the treatment of ovarian cancer

Review decision

The Institute was proposing that the guidance should be transferred to the static guidance list.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal and the guidance will be transferred on to the static list.